Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial
Julien Edeline(Inserm), Éveline Boucher(Boston Scientific (United States)), Karine Bouhier‐Leporrier(Université Paris Cité), J. Watelet(Centre Hospitalier Régional et Universitaire de Nancy), J.-L. Jouve(CHU Dijon Bourgogne), J.F. Seitz(Assistance Publique Hôpitaux de Marseille), David Malka(Inserm), Trevor Stanbury(UniCancer Group), J Phelip(Centre Hospitalier Universitaire de Saint-Étienne), Eric Assénat, Lætitia Fartoux(Asan Medical Center), Véronique Guerin‐Meyer(Institut de Cancérologie de l'Ouest), Franck Bonnetain(Azienda Ospedaliera Universitaria Pisana), Pascal Hammel(Hôpital Paul-Brousse), M. Benabdelghani(Levi Strauss (United States)), Béata Juzyna(UniCancer Group), Aurélie Bertaut(Institut de Cancérologie de Bourgogne), Christophe Louvet(Institute Mutualiste Montsouris), JP Joly(Centre Hospitalier Universitaire Amiens-Picardie), Roger Faroux(Roche (Switzerland))
Cited by 4
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k